Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma

Inclusion Criteria

• •1. 18-80 year of age
• •2. Body weight ≥40 kg
• •3. Diagnosed with asthma ≥12 months
• •4. Received a total daily dose of medium/high dose of ICS for more than 3 months steadily
• •5. At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.
• •6. Morning pre-BD FEV1 \<80% but ≥35% predicted normal
• •7. Evidence of asthma as documented by reversibility test or change of PEF.
• •8. Documented history of at least 1 asthma exacerbation events within 12 months.
• •9. ACQ-5 score ≥1.5 at screening and on day of randomization